Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Blawski R, Vokshi BH, Guo X, Kittane S, Sallaku M, Chen W, Gjyzari M, Cheung T, Zhang Y, Simpkins C, Zhou W, Kulick A, Zhao P, Wei M, Shivashankar P, Prioleau T, Razavi P, Koche R, Rebecca VW, de Stanchina E, Castel P, Chan HM, Scaltriti M, Cocco E, Ji H, Luo M, Toska E.
Blawski R, et al. Among authors: rebecca vw.
Cell Rep. 2024 May 28;43(5):114174. doi: 10.1016/j.celrep.2024.114174. Epub 2024 May 2.
Cell Rep. 2024.
PMID: 38700982
Free PMC article.